Table 1.

Baseline Characteristics by Treatment Group

Placebo (N = 18)Metformin (N = 19)
Age, y15.5 (2.2)15.8 (2.1)
Sex: female, n (%)8 (44)12 (63)
Race/ethnicity, n (%)
 White13 (72)16 (84)
 Non-Hispanic black1 (6.3)1 (5.3)
 Hispanic white3 (18.8)2 (10.5)
 Other1 (6)
Tanner stage (4 or 5), n (%)15 (81)17 (91)
Duration of diabetes, y7.2 ± 3.16.9 ± 3.7
Weight, kg85.2 ± 17.786.7 ± 17.0
FFM, kg49.8 ± 9.049.8 ± 9.9
Waist circumference, cm98.3 ± 13.397.0 ± 13.0
BMI, percentile96.7 ± 2.396.3 ± 2.5
BMI z score1.9 ± 0.31.9 ± 0.4
HbA1c, %8.4 ± 1.09.2 ± 1.1a
HbA1c, mmol/mol68.3 ± 8.677 ± 9.7a
TDI/kg1.03 (0.87, 1.16)1.03 (0.91, 1.31)
Steady-state GIR, corrected for serum glucose, mg/kg/min5.0 ± 2.54.8 ± 2.8
Placebo (N = 18)Metformin (N = 19)
Age, y15.5 (2.2)15.8 (2.1)
Sex: female, n (%)8 (44)12 (63)
Race/ethnicity, n (%)
 White13 (72)16 (84)
 Non-Hispanic black1 (6.3)1 (5.3)
 Hispanic white3 (18.8)2 (10.5)
 Other1 (6)
Tanner stage (4 or 5), n (%)15 (81)17 (91)
Duration of diabetes, y7.2 ± 3.16.9 ± 3.7
Weight, kg85.2 ± 17.786.7 ± 17.0
FFM, kg49.8 ± 9.049.8 ± 9.9
Waist circumference, cm98.3 ± 13.397.0 ± 13.0
BMI, percentile96.7 ± 2.396.3 ± 2.5
BMI z score1.9 ± 0.31.9 ± 0.4
HbA1c, %8.4 ± 1.09.2 ± 1.1a
HbA1c, mmol/mol68.3 ± 8.677 ± 9.7a
TDI/kg1.03 (0.87, 1.16)1.03 (0.91, 1.31)
Steady-state GIR, corrected for serum glucose, mg/kg/min5.0 ± 2.54.8 ± 2.8

Data are shown as mean ± SD or median (25th percentile, 75th percentile).

a

P < 0.05 to 0.01.

Table 1.

Baseline Characteristics by Treatment Group

Placebo (N = 18)Metformin (N = 19)
Age, y15.5 (2.2)15.8 (2.1)
Sex: female, n (%)8 (44)12 (63)
Race/ethnicity, n (%)
 White13 (72)16 (84)
 Non-Hispanic black1 (6.3)1 (5.3)
 Hispanic white3 (18.8)2 (10.5)
 Other1 (6)
Tanner stage (4 or 5), n (%)15 (81)17 (91)
Duration of diabetes, y7.2 ± 3.16.9 ± 3.7
Weight, kg85.2 ± 17.786.7 ± 17.0
FFM, kg49.8 ± 9.049.8 ± 9.9
Waist circumference, cm98.3 ± 13.397.0 ± 13.0
BMI, percentile96.7 ± 2.396.3 ± 2.5
BMI z score1.9 ± 0.31.9 ± 0.4
HbA1c, %8.4 ± 1.09.2 ± 1.1a
HbA1c, mmol/mol68.3 ± 8.677 ± 9.7a
TDI/kg1.03 (0.87, 1.16)1.03 (0.91, 1.31)
Steady-state GIR, corrected for serum glucose, mg/kg/min5.0 ± 2.54.8 ± 2.8
Placebo (N = 18)Metformin (N = 19)
Age, y15.5 (2.2)15.8 (2.1)
Sex: female, n (%)8 (44)12 (63)
Race/ethnicity, n (%)
 White13 (72)16 (84)
 Non-Hispanic black1 (6.3)1 (5.3)
 Hispanic white3 (18.8)2 (10.5)
 Other1 (6)
Tanner stage (4 or 5), n (%)15 (81)17 (91)
Duration of diabetes, y7.2 ± 3.16.9 ± 3.7
Weight, kg85.2 ± 17.786.7 ± 17.0
FFM, kg49.8 ± 9.049.8 ± 9.9
Waist circumference, cm98.3 ± 13.397.0 ± 13.0
BMI, percentile96.7 ± 2.396.3 ± 2.5
BMI z score1.9 ± 0.31.9 ± 0.4
HbA1c, %8.4 ± 1.09.2 ± 1.1a
HbA1c, mmol/mol68.3 ± 8.677 ± 9.7a
TDI/kg1.03 (0.87, 1.16)1.03 (0.91, 1.31)
Steady-state GIR, corrected for serum glucose, mg/kg/min5.0 ± 2.54.8 ± 2.8

Data are shown as mean ± SD or median (25th percentile, 75th percentile).

a

P < 0.05 to 0.01.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close